吉西他滨联合顺铂治疗晚期非小细胞肺癌

The clinical observation of Gemcitabine combined with Cisplatin in the treatment of advanced non-small cell lung cancer

目的观察吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效及毒副作用。方法选择晚期非小细胞肺癌患者37例，给予吉西他滨1000－1250mg／m2，静滴，第1天及第8天；顺铂80mg／m2，静滴，第1天或分第1—3天。21d为1周期，至少完成2周期。结果全组完全缓解（CR）0例，部分缓解（PR）16例，稳定（sD）13例，总有效率（CR＋PR）43．2％，肿瘤控制率（CR＋PR＋SD）78．4％。毒副作用主要是骨髓抑制及恶心、呕吐。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌安全有效，毒副作用可以耐受。

Objective To evaluate the efficacy and toxicity of Gemeitahine combined with Cisplatin in the treatment of advanced non-small cell lung cancer. Methods Gemeitabine 1 000 - 1 250mg/m2,intravenous infusion, on dl,8, Cisplatin 80mg/m2,intravenous infusion, on d l or d1 - 3,the regimen was repeated every 21 days, completed at least 2 cycles. Results Thirty-seven patients were evaluated. None achieved CR, 16 patients achieved PR,13 patients achieved SD,the overall response rate（ CR ＋ PR） was 43.2% ,and the disease control rate（ CR ＋ PR ＋ SD） was 78.4%. The most common toxieities were bone marrow suppression, nausea and vomiting. Coneluslon The regimen of Gemeitabine combined with Cisplatin in the treatment of advanced non-small cell lung cancer was safe and effective, and the toxicity could be tolerated.